Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr. Reddy’s launches Difluprednate Ophthalmic Emulsion in US market

Date: 27-01-2023

Dr. Reddy’s Laboratories has launched Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).

The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA. Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.